Core Viewpoint - Xiangsheng Medical (688358) announced a cash dividend distribution of 10 CNY per 10 shares, totaling 111,874,753 CNY, which represents 79.62% of the company's net profit attributable to shareholders for the year [1][2][4] Trading Information Summary - On July 8, 2025, Xiangsheng Medical's stock closed at 29.9 CNY, with a slight decline of 0.07%. The turnover rate was 0.93%, with a trading volume of 10,400 shares and a total transaction value of 31,227,400 CNY [1] - The fund flow on the same day showed a net outflow of 480,670 CNY from main funds, accounting for 15.39% of the total transaction value, while retail funds had a net inflow of 598,990 CNY, representing 19.18% of the total [1][4] Company Announcement Summary - Xiangsheng Medical's 2024 annual profit distribution plan includes a cash dividend of 10 CNY per 10 shares (before tax), with the base for distribution being 111,874,753 shares after deducting 249,784 shares held in the repurchase account [1][2] - The dividend distribution will not involve capital reserve conversion into share capital or the issuance of bonus shares. The record date for the dividend is July 14, 2025, and the ex-dividend date and payment date are both set for July 15, 2025 [1][2]

Core Viewpoint - The legal opinion issued by Shanghai Tongli Law Firm confirms that the differentiated dividend distribution plan proposed by Wuxi Xiangsheng Medical Technology Co., Ltd. complies with relevant laws and regulations, and does not harm the interests of the company and its shareholders [4][7]. Group 1: Differentiated Dividend Distribution - The differentiated dividend distribution is necessitated by the company's share repurchase plan, which involves using self-owned funds to repurchase A-shares for employee stock ownership plans, with a repurchase price not exceeding RMB 62.05 per share and a total repurchase amount between RMB 10 million and RMB 20 million [4][5]. - As of the date of the legal opinion, the company has repurchased a total of 249,784 shares, which will not participate in the profit distribution for the fiscal year 2024, leading to a discrepancy between the total share capital and the shares participating in profit distribution [5][6]. Group 2: Impact on Share Price - The differentiated dividend distribution will adjust the base for profit distribution by deducting the shares held in the repurchase account from the total share capital, while maintaining the per-share distribution ratio [6]. - The estimated impact of the differentiated dividend on the ex-dividend reference price is less than 1%, indicating that it will not significantly affect the company's share price [6][7]. Group 3: Legal Compliance - The legal opinion asserts that the differentiated dividend distribution does not violate the Company Law, Securities Law, self-regulatory guidelines, or the company's articles of association, and confirms that it does not harm the interests of the company or its shareholders [4][7].

Core Points - The company plans to distribute a cash dividend of 1 yuan per share to all shareholders, approved at the 2024 annual general meeting on May 16, 2025 [1][2] - The total number of shares eligible for the dividend is 111,874,753 shares after excluding shares in the company's repurchase account, resulting in a total cash dividend distribution of 111,874,753 yuan, which accounts for 79.62% of the company's net profit attributable to shareholders for the year [2][3] - The company will not issue bonus shares or increase capital reserves this year [2] Dividend Distribution Details - The cash dividend distribution will be based on the total number of shares registered by the close of trading on the equity registration date [1][3] - The reference price for ex-dividend trading will be calculated using the formula: (previous closing price - cash dividend) / (1 + change in circulating shares ratio), with the circulating shares ratio being 0 due to no changes in circulating shares [3] - The virtual cash dividend per share is approximately 0.9978 yuan, calculated based on the total shares participating in the distribution [3] Tax Implications - For individual shareholders holding shares for over one year, the cash dividend is exempt from personal income tax, resulting in a net distribution of 1 yuan per share [6][7] - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution, but tax will be calculated and withheld upon the sale of shares [6][8] - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net cash dividend of 0.9 yuan per share [7][8]

上海市通力律师事务所 关于无锡祥生医疗科技股份有限公司 差异化分红事项之专项法律意见书 致: 无锡祥生医疗科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受无锡祥生医疗科技股份有限公司(以下 简称"祥生医疗"或"公司")的委托, 指派本所孙文律师、李昱程律师(以下合称"本所律 师")根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券 法》(以下简称"《证券法》")、《上海证券交易所上市公司自律监管指引第 7 号——回购 股份》(以下简称"《自律监管指引》")、《上海证券交易所上市公司自律监管指南第 2 号 ——业务办理》等法律、法规及规范性文件(以下简称"法律、法规及规范性文件", 该等 法律、法规及规范性文件不包括香港特别行政区、澳门特别行政区和台湾地区的法律法规) 以及《无锡祥生医疗科技股份有限公司章程》(以下简称"《公司章程》")的规定, 就祥生 医疗 2024 年度利润分配所涉及的差异化分红事项(以下简称"本次差异化分红")相关事项 出具法律意见。 为出具本法律意见书, 本所律师已经严格履行法定职责, 遵循了勤勉尽责和诚实信用 原则, 对祥生医疗本次差异化分红所涉 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2025-017 无锡祥生医疗科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/14 | 2025/7/15 | 2025/7/15 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 16 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东（无 锡祥生医疗科技股份有限公司回购专用证券账户除外）。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 上市公司自律监管指引第 7 号——回购股份》等相关法律、行政法规、部门规章 是否涉及差异化分红送转：是 ...

Company Overview - Xiangsheng Medical closed at 28.1 yuan, down 2.09%, with a rolling PE ratio of 23.07 times and a total market value of 3.151 billion yuan [1] - The company specializes in the research, manufacturing, and sales of ultrasound medical imaging equipment [1] - Xiangsheng Medical was selected as a "Little Giant" enterprise for the 2024 National Specialized and Innovative Enterprises [1] Financial Performance - For Q1 2025, the company reported operating revenue of 128 million yuan, a year-on-year decrease of 9.16%, and a net profit of 41.6145 million yuan, down 8.62% year-on-year, with a gross profit margin of 61.33% [1] Shareholder Information - As of March 31, 2025, the number of shareholders for Xiangsheng Medical was 6,509, an increase of 1,499 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 49.10 times, with a median of 36.43 times, placing Xiangsheng Medical at the 52nd position in the industry ranking [1][2] - The industry average market value is 10.51 billion yuan, while the median is 4.892 billion yuan [2]

6月9日，祥生医疗今日收盘30.45元，上涨2.66%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到25.00倍，创43天以来新低，总市值34.14亿元。 无锡祥生医疗科技股份有限公司的主营业务是超声医学影像设备的研发、制造和销售。公司的主要产品 是超声医学影像设备。公司入选2024年度国家专精特新"小巨人"企业。 最新一期业绩显示，2025年一季报，公司实现营业收入1.28亿元，同比-9.16%；净利润4161.45万元，同 比-8.62%，销售毛利率61.33%。 来源：金融界 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均50.64倍，行业中值37.05倍，祥生医疗排 名第54位。 截至2025年一季报，共有15家机构持仓祥生医疗，其中基金10家、其他5家，合计持股数5830.14万股， 持股市值18.03亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)54祥生医疗25.0024.302.3334.14亿行业平均 50.6449.074.68109.10亿行业中值37.0537.632.5050.67亿1天益医疗-1817.92-3113.901.9423.17亿2 ...

Core Viewpoint - The company, Xiangsheng Medical, is increasing its R&D investment and has introduced innovative products in the field of ultrasound technology, particularly focusing on breast cancer screening and maternal health solutions. Group 1: Financial Performance - As of May 23, 2025, Xiangsheng Medical's stock closed at 28.63 yuan, up 0.74% from the previous week [1] - The company's total market capitalization is 3.21 billion yuan, ranking 93rd out of 126 in the medical device sector and 3960th out of 5148 in the A-share market [1] Group 2: R&D Investment - In 2024, the company plans to increase its R&D expenditure to nearly 80 million yuan, which represents 16.99% of its operating revenue [2][3] - The company will authorize 48 new patents in 2024, including 30 new invention patents, and will file 66 new intellectual property applications, with 15 being invention patent applications [2][3] Group 3: Product Development - The company has launched a "Breast Artificial Intelligence Ultrasound Robot" aimed at addressing the challenges of mass screening for breast cancer in China, integrating ultrasound, robotics, and AI technology [2][3] - In the field of obstetrics, the company has developed an intelligent solution that automatically tracks fetal position, recognizes growth indicators, and generates fetal examination reports [2][3]

Industry Overview and Core Value - AI in healthcare utilizes machine learning and computer vision to analyze medical data, aiming to enhance efficiency, reduce costs, and optimize patient experience [1][14] - The Chinese government has introduced policies to promote AI integration in healthcare, identifying 84 application scenarios [1][22] Development History and Market Size - The development of AI in healthcare in China can be divided into three phases: the nascent phase (1978-2015), the starting phase (2015-2021), and the exploratory phase (2021-present) [2][25] - The market size for AI healthcare in China is projected to reach 115.7 billion yuan by 2025 and 159.8 billion yuan by 2028, with a CAGR of 10.5% [2][39] Industry Chain and Segmentation - The AI healthcare industry chain includes upstream (data, algorithms, computing power), midstream (computer vision, NLP), and downstream (imaging, pharmaceuticals, health management) [3][43] - Key segments include: - AI Medical Imaging: Expected market size of approximately 7.45 billion yuan in 2024, growing to 23.57 billion yuan by 2026 [3] - AI Pharmaceuticals: Global market size projected at 2.994 billion USD in 2024 [3] - AI Health Management: Market size nearing 1.4 trillion yuan in 2024 [3] Challenges and Future Trends - Current challenges include insufficient data standardization, privacy protection, and high implementation costs [4] - Future trends involve: - Deepening technology integration, such as combining large models with multimodal technologies [4] - Promoting domestic production and self-control in hardware and algorithms [4] - Expanding application scenarios from hospitals to grassroots healthcare [4] - Policy-driven commercialization in areas like telemedicine and imaging recognition [4] Representative Company Layout - Key companies in the AI healthcare sector include: - Xiangsheng Medical: Portable ultrasound devices recognized internationally [5] - RunDa Medical: Integration of in vitro diagnostics with AI [5] - United Imaging: High-end imaging equipment with over 20% market share [5] - iFlytek Medical: Comprehensive coverage of the medical process with its large model [5]

Meeting Overview - The shareholder meeting of Wuxi Xiangsheng Medical Technology Co., Ltd. was held on May 16, 2025, at the company's conference room [1] - A total of 40 ordinary shareholders attended the meeting, representing 82,221,541 voting rights, which accounts for 73.3305% of the total voting rights of the company [1] Voting Results - All non-cumulative voting proposals were approved with a significant majority, including: - 99.9857% of ordinary shareholders voted in favor of the proposals, with only 0.0143% against [2] - The voting results for the financial budget report for 2025 also showed a similar trend, with 99.9857% approval [2] - The meeting's voting procedures complied with the Company Law and the company's articles of association, confirming the legality and validity of the meeting [3] Legal Compliance - The lawyers present at the meeting confirmed that the convening and voting procedures adhered to relevant laws and regulations, ensuring the legitimacy of the meeting and its outcomes [3]